Zürcher Nachrichten - US panel weighs authorizing Covid vaccines for youngest children

EUR -
AED 4.243598
AFN 76.263586
ALL 93.252722
AMD 423.077847
AOA 1060.756747
ARS 1729.009179
AUD 1.63715
AWG 2.082804
AZN 1.965146
BAM 1.957373
BBD 2.326069
BDT 142.954868
BHD 0.435742
BIF 3457.859125
BMD 1.155508
BND 1.48089
BOB 14.025967
BRL 5.938617
BSD 1.154928
BTN 109.794748
BWP 15.661517
BYN 3.415745
BYR 22647.966202
BZD 2.322716
CAD 1.618749
CDF 2612.604653
CHF 0.93223
CLF 0.026748
CLP 1056.157931
CNY 7.799775
CNH 7.796366
COP 3677.625283
CRC 523.720823
CUC 1.155508
CUP 30.620975
CVE 110.577359
CZK 24.184522
DJF 205.35721
DKK 7.475388
DOP 67.30804
DZD 153.466204
EGP 57.550907
ERN 17.332627
ETB 184.823403
FJD 2.553308
FKP 0.858801
GBP 0.857994
GEL 3.021622
GGP 0.858801
GHS 13.548336
GIP 0.858801
GMD 84.931759
GNF 10148.261152
GTQ 8.809078
GYD 241.584711
HKD 9.063364
HNL 31.036971
HRK 7.533572
HTG 151.001333
HUF 361.860769
IDR 20659.336108
ILS 3.470858
IMP 0.858801
INR 109.864533
IQD 1514.293863
IRR 1588593.057877
ISK 141.815325
JEP 0.858801
JMD 183.527469
JOD 0.819276
JPY 182.208653
KES 149.488533
KGS 101.048565
KHR 4682.700886
KMF 493.401915
KRW 1644.196411
KWD 0.357306
KYD 0.962469
KZT 541.953128
LAK 26120.269022
LBP 103475.784612
LKR 387.551407
LRD 209.436313
LSL 18.846604
LTL 3.411917
LVL 0.698955
LYD 7.354819
MAD 10.762117
MDL 20.066037
MGA 4971.568067
MKD 61.524919
MMK 2425.761657
MNT 4157.747973
MOP 9.330357
MRU 46.312797
MUR 54.285874
MVR 17.852389
MWK 2007.117959
MXN 19.919233
MYR 4.724922
MZN 73.848488
NAD 18.858
NGN 1574.334577
NIO 42.504153
NOK 11.010667
NPR 175.672918
NZD 1.962891
OMR 0.444286
PAB 1.154903
PEN 3.9114
PGK 5.111391
PHP 70.137026
PKR 321.001615
PLN 4.301566
PYG 6887.534304
QAR 4.212695
RON 5.246245
RSD 117.344628
RUB 93.568896
RWF 1693.975431
SAR 4.336079
SBD 9.323045
SCR 16.772158
SDG 693.886139
SEK 10.959647
SGD 1.480021
SLE 28.422197
SOS 693.885368
SRD 43.525699
STD 23916.692567
STN 24.843432
SVC 10.10512
SZL 18.846478
THB 38.224452
TJS 10.659434
TMT 4.04428
TND 3.367128
TRY 54.991339
TTD 7.834295
TWD 37.299582
TZS 3062.095139
UAH 51.681828
UGX 4307.461152
USD 1.155508
UYU 46.437314
UZS 13790.993709
VES 871.497494
VND 30333.2531
VUV 138.157226
WST 3.162341
XAF 656.481659
XAG 0.018569
XAU 0.000271
XCD 3.122819
XCG 2.081381
XDR 0.817469
XOF 656.91048
XPF 119.331742
YER 273.71111
ZAR 18.847672
ZMK 10400.959138
ZMW 22.046238
ZWL 372.073259
  • CMSC

    -0.0600

    21.73

    -0.28%

  • RYCEF

    0.6000

    21

    +2.86%

  • NGG

    -0.1600

    80.26

    -0.2%

  • BCE

    0.0600

    22.06

    +0.27%

  • GSK

    -0.0700

    51.46

    -0.14%

  • BTI

    0.1500

    59.27

    +0.25%

  • RBGPF

    0.0000

    69.74

    0%

  • RELX

    -0.1900

    36.61

    -0.52%

  • AZN

    5.8800

    161.5

    +3.64%

  • RIO

    2.5000

    101.51

    +2.46%

  • CMSD

    0.0200

    22.04

    +0.09%

  • VOD

    -0.3800

    15.31

    -2.48%

  • BCC

    -1.6900

    84.8

    -1.99%

  • BP

    -1.2300

    41.21

    -2.98%

  • JRI

    -0.0500

    12.67

    -0.39%

US panel weighs authorizing Covid vaccines for youngest children
US panel weighs authorizing Covid vaccines for youngest children / Photo: Frederic J. BROWN - AFP/File

US panel weighs authorizing Covid vaccines for youngest children

After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.

Text size:

Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.

Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."

Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.

Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.

They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.

Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.

But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.

There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.

White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.

Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.

Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.

Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.

Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."

S.Scheidegger--NZN